<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8135">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00855309</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000633817</org_study_id>
    <secondary_id>P30CA012197</secondary_id>
    <secondary_id>CCCWFU-98608</secondary_id>
    <secondary_id>IRB00007690</secondary_id>
    <nct_id>NCT00855309</nct_id>
  </id_info>
  <brief_title>Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia</brief_title>
  <official_title>Low Dose Versus Weight-based Intravenous Acyclovir for Herpes Simplex Virus Prophylaxis in the Neutropenic Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Comprehensive Cancer Center of Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Comprehensive Cancer Center of Wake Forest University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Acyclovir may be effective in preventing herpes simplex virus infection in
      patients with neutropenia.

      PURPOSE: This randomized phase III trial is studying the side effects of acyclovir and is
      comparing two doses of acyclovir in preventing herpes simplex virus infection in patients
      with neutropenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To determine the difference in nephrotoxicity between low-dose and weight-based
           intravenous acyclovir sodium as herpes simplex virus infection prophylaxis in patients
           with neutropenia.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive weight-based IV acyclovir sodium every 8 or 12 hours.

        -  Arm II: Patients receive low-dose IV acyclovir sodium every 8 or 12 hours. Treatment
           continues for approximately 2 weeks unless clinical herpes simplex virus infection is
           confirmed or the patient is no longer neutropenic.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Number of Participants Experiencing Incidence of Nephrotoxicity, Defined as a Serum Creatinine ≥ 2 Times the Patient's Baseline</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Herpes Simplex</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive weight-based IV acyclovir sodium every 8 or 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive low-dose IV acyclovir sodium every 8 or 12 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acyclovir sodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be 18 years of age or older.

          -  Receiving treatment in inpatient oncology services at Wake Forest University Baptist
             Medical Center

          -  Receiving chemotherapy or have received chemotherapy within the past 2 weeks

          -  Seropositive herpes simplex virus (HSV)-1 or HSV-2 immunoglobulin antibody assay

          -  Creatinine clearance ≥ 50 mL/min

          -  Intravenous acyclovir sodium therapy is deemed necessary by the physician based upon
             clinical judgement (i.e., mucositis, vomiting, decreased GI absorption)

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Hypersensitivity to acyclovir sodium

          -  High tumor burden (i.e., WBC &gt; 50,000/mm^3 at admission)

          -  Neutropenic, defined as one of the following:

          -  ANC &lt; 500/mm^3

          -  ANC &lt; 1,000/mm^3 with a predicted decrease to 500/mm^3

          -  Active HSV infection, as evidenced by any of the following:

          -  Positive HSV cultures

          -  Oral lesions

          -  Receiving 5 mg/kg acyclovir sodium every 8 hours
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Jay Brown, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Cancer Center of Wake Forest University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>October 22, 2015</lastchanged_date>
  <firstreceived_date>March 3, 2009</firstreceived_date>
  <firstreceived_results_date>September 24, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemotherapeutic agent toxicity</keyword>
  <keyword>renal toxicity</keyword>
  <keyword>infection</keyword>
  <keyword>neutropenia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Weight-based IV Acyclovir</title>
          <description>Patients receive weight-based IV acyclovir sodium every 8 or 12 hours.</description>
        </group>
        <group group_id="P2">
          <title>Low-dose IV Acyclovir</title>
          <description>Patients receive low-dose IV acyclovir sodium every 8 or 12 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>patient never recieved drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Patients receive weight-based IV acyclovir sodium every 8 or 12 hours.</description>
        </group>
        <group group_id="B2">
          <title>Arm II</title>
          <description>Patients receive low-dose IV acyclovir sodium every 8 or 12 hours.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="57"/>
                <measurement group_id="B2" value="55"/>
                <measurement group_id="B3" value="112"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
                <measurement group_id="B2" value="39"/>
                <measurement group_id="B3" value="81"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="55.3" spread="13.5"/>
                <measurement group_id="B2" value="53.3" spread="14.4"/>
                <measurement group_id="B3" value="54.4" spread="14.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="24"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="51"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="28"/>
                <measurement group_id="B3" value="61"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="57"/>
                <measurement group_id="B2" value="55"/>
                <measurement group_id="B3" value="112"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Incidence of Nephrotoxicity, Defined as a Serum Creatinine ≥ 2 Times the Patient's Baseline</title>
        <time_frame>24 hours</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive weight-based IV acyclovir sodium every 8 or 12 hours.</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Patients receive low-dose IV acyclovir sodium every 8 or 12 hours.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Experiencing Incidence of Nephrotoxicity, Defined as a Serum Creatinine ≥ 2 Times the Patient's Baseline</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>Patients receive weight-based IV acyclovir sodium every 8 or 12 hours.</description>
        </group>
        <group group_id="E2">
          <title>Arm II</title>
          <description>Patients receive low-dose IV acyclovir sodium every 8 or 12 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrotoxicity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>per the protocol, only nephrotoxicities (as measured by Creatinine increase over baseline were observed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>LeAnne Kenndy, PharmD</name_or_title>
      <organization>Comprehensive Cancer Center of Wake Forest University</organization>
      <phone>336-713-3416</phone>
      <email>lakenned@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
